A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly‘s stock is still recovering after the drugmaker released trial data earlier this month on its closely watched obesity pill that underwhelmed Wall Street. In a key late-stage trial,…
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Markets: Stocks aren’t moving much Monday as Wall Street waits on retail earnings and a speech from Fed Chair Jay Powell later in the week. Monday’s…
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Thursday’s key moments. 1. Tech stocks rose Thursday on the broad exemptions included in the chip tariffs that President Donald Trump announced after Wednesday’s close. Club name Nvidia jumped 2%. Shares of Apple…
Eli Lilly on Thursday said the highest dose of its daily obesity pill helped patients lose almost 12% of their body weight, or roughly 27 pounds, at 72 weeks in a late-stage trial, paving the way for its entrance into the market. The pill’s weight loss was 11.2% when analyzing all patients regardless of discontinuations….
Boxes of Ozempic and Wegovy made by Novo Nordisk at a pharmacy in London on March 8, 2024. Hollie Adams | Reuters Novo Nordisk on Wednesday posted second-quarter sales broadly in line with expectations, after last week cutting its full-year guidance and announcing its new CEO. Overall revenues rose 13% year-on-year at constant exchange rates…
A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Hollie Adams | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. For…
The Hers app arranged on a smartphone in New York, US, on Wednesday, Feb. 12, 2025. Gabby Jones | Bloomberg | Getty Images Shares of Hims & Hers Health fell 9% in extended trading on Monday after the telehealth company reported second-quarter results that missed Wall Street’s expectations for revenue. Here’s how the company did…
Wall Street ended a busy week of earnings, economic data and policy decisions with a thud, as a weak jobs report renewed concerns about the health of the U.S. economy in the face of President Donald Trump’s ever-shifting tariff policy. In the week ahead, investors will look to the latest batch of earnings for additional…
It was a dizzying week on Wall Street. The S & P 500 closed this past Monday at a record high and then went on a four-session losing streak. Friday was particularly unsettling as terrible jobs data slammed the market and triggered President Donald Trump . Trump started the day by slamming Federal Reserve Chairman…
CNBC’s Jim Cramer walked investors through another week of earnings season, honing in on reports from Palantir, Berkshire Hathaway, Disney and Eli Lilly. “We’re still in earnings Hades, but at least it’s getting a little cooler out there,” he said. “That’s right, we’ve now gotten over the hump of the big-time growth stocks, the hyperscalers,…
